NeoGenomics, Inc. - Common Stock (NQ:NEO)

16.69 +0.10 (+0.60%)

Delayed Quote Updated: 4:00 PM EDT, Oct 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about NeoGenomics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

NeoGenomics Expands Indica Labs Partnership to Scale AI-Powered Digital Pathology

October 15, 2026

From NeoGenomics, Inc.

Via Business Wire

NeoGenomics to Report Third Quarter 2026 Financial Results on October 28, 2026

October 14, 2026

From NeoGenomics, Inc.

Via Business Wire

3 Small-Cap Stocks with Questionable Fundamentals

October 13, 2026

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th...

Via StockStory

Why NeoGenomics (NEO) Stock Is Up Today

October 06, 2026

What Happened? Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) jumped 3.6% in the pre-market session after the company announced an ...

Via StockStory

Topics Regulatory Compliance

NeoGenomics (NASDAQ:NEO): Quality Stock After Q2 Earnings Beat and Raised Guidance ↗

July 28, 2026

Via Chartmill

Topics Earnings

NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan

October 05, 2026

From NeoGenomics, Inc.

Via Business Wire

3 Healthcare Stocks We’re Skeptical Of

September 23, 2026

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva...

Via StockStory

3 Reasons NEO is Risky and 1 Stock to Buy Instead

September 22, 2026

What a time it’s been for NeoGenomics. In the past six months alone, the company’s stock price has increased by a massive 138%, reaching $19.30 per share. Th...

Via StockStory

Topics Bankruptcy Supply Chain

NeoGenomics Highlights NGS, MRD Growth Strategy at Morgan Stanley Conference ↗

September 20, 2026

NeoGenomics (NASDAQ:NEO) executives outlined the company’s strategy to expand its role in community-based precision oncology, emphasizing growth in next-generation sequencing, minimal residual disease...

Via MarketBeat

September 18, 2026

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t...

Via StockStory

Topics Economy

A Look Back at Testing & Diagnostics Services Stocks’ Q2 Earnings: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Pack

September 10, 2026

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at NeoGenomics (NASDAQ:NEO) and ...

Via StockStory

NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

September 01, 2026

From NeoGenomics, Inc.

Via Business Wire

NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring

August 26, 2026

From NeoGenomics, Inc.

Via Business Wire

3 Unprofitable Stocks Walking a Fine Line

August 21, 2026

Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th...

Via StockStory

3 Stocks Under $50 with Open Questions

August 06, 2026

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However...

Via StockStory

3 Healthcare Stocks with Questionable Fundamentals

August 03, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not on...

Via StockStory

Why NeoGenomics (NEO) Stock Is Up Today

July 29, 2026

What Happened? Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) jumped 15.8% in the afternoon session after the company reported seco...

Via StockStory

3 of Wall Street’s Favorite Stocks with Questionable Fundamentals

July 29, 2026

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember...

Via StockStory

NeoGenomics Q2 Earnings Call Highlights ↗

July 28, 2026

NeoGenomics (NASDAQ:NEO) raised its full-year 2026 revenue and adjusted EBITDA guidance after reporting second-quarter revenue growth that exceeded its prior outlook, led by higher-value clinical...

Via MarketBeat

Topics Earnings

NeoGenomics’s (NASDAQ:NEO) Q2 CY2026: Beats On Revenue

July 28, 2026

Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 11.2% year on...

Via StockStory

NeoGenomics Reports Second Quarter 2026 Results

July 28, 2026

From NeoGenomics, Inc.

Via Business Wire

NeoGenomics (NEO) Q2 Earnings Report Preview: What To Look For

July 26, 2026

Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be announcing earnings results this Tuesday afternoon. Here’s what you need to know. NeoG...

Via StockStory

Topics Artificial Intelligence

1 Momentum Stock with Solid Fundamentals and 2 We Avoid

July 23, 2026

The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, pos...

Via StockStory

NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS

July 20, 2026

From NeoGenomics, Inc.

Via Business Wire

3 Small-Cap Stocks with Questionable Fundamentals

July 15, 2026

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and...

Via StockStory

NeoGenomics (NEO) Stock Trades Up, Here Is Why

July 09, 2026

What Happened? Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) jumped 3.4% in the afternoon session after the company announced the ...

Via StockStory

Topics Intellectual Property Lawsuit

NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer

July 09, 2026

From NeoGenomics, Inc.

Via Business Wire

NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026

July 07, 2026

From NeoGenomics, Inc.

Via Business Wire

A Look Back at Testing & Diagnostics Services Stocks’ Q1 Earnings: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Pack

June 25, 2026

Looking back on testing & diagnostics services stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including NeoGenomics (NASDAQ:NEO) a...

Via StockStory

NeoGenomics Appoints Carolyn Starrett to its Board of Directors

June 25, 2026

From NeoGenomics, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.